

1 **The mycobacterial mutasome: composition and recruitment in live cells**

2 Sophia Gessner^{1,2§}, Zela Martin^{1,2,3§}, Michael A. Reiche^{1,2,4§}, Joana A. Santos⁵, Neeraj Dhar^{3,*}, Ryan
3 Dinkele^{1,2}, Timothy De Wet^{1,2,6}, Atondaho Ramudzuli^{1,2}, Saber Anosheh^{1,2,†} Dirk M. Lang⁷, Jesse
4 Aaron⁴, Teng-Leong Chew⁴, Jennifer Herrmann^{8,9}, Rolf Müller^{8,9}, John D. McKinney³, Roger
5 Woodgate¹⁰, Valerie Mizrahi^{1,2,11}, Meindert H. Lamers⁵, Digby F. Warner^{1,2,11#}

6 ¹SAMRC/NHLS/UCT Molecular Mycobacteriology Research Unit, DSI/NRF Centre of Excellence for
7 Biomedical TB Research, Department of Pathology, University of Cape Town, South Africa; ²Institute
8 of Infectious Disease and Molecular Medicine, University of Cape Town, South Africa; ³Laboratory of
9 Microbiology and Microsystems, School of Life Sciences, Swiss Federal Institute of Technology in
10 Lausanne (EPFL), Lausanne, Switzerland; ⁴Advanced Imaging Center, Howard Hughes Medical
11 Institute, United States of America; ⁵Department of Cell and Chemical Biology, Leiden University
12 Medical Center, The Netherlands; ⁶Department of Integrative Biomedical Sciences, University of Cape
13 Town, South Africa; ⁷Confocal and Light Microscope Imaging Facility, Department of Human Biology,
14 University of Cape Town, South Africa; ⁸Helmholtz Institute for Pharmaceutical Research Saarland
15 (HIPS), Helmholtz Centre for Infection Research, Germany; ⁹German Centre for Infection Research
16 (DZIF), Partner Site Hannover-Braunschweig, Germany; ¹⁰Laboratory of Genomic Integrity, National
17 Institute of Child Health and Human Development, National Institutes of Health, United States of
18 America; ¹¹Wellcome Centre for Infectious Diseases Research in Africa, University of Cape Town,
19 South Africa.

20 [§]These authors contributed equally

21 ^{*}Present address: Vaccine and Infectious Disease Organization (VIDO), University of Saskatchewan,
22 120 Veterinary Road, Saskatoon, SK, S7N 5E3, Canada

23 [†]Present address: Department of Chemistry and Umeå Centre for Microbial Research, Umeå
24 University, 90187, Umeå, Sweden.

25 [#]For correspondence: digby.warner@uct.ac.za

26 **ABSTRACT**

27 A DNA damage-inducible mutagenic gene cassette has been implicated in the emergence of drug
28 resistance in *Mycobacterium tuberculosis* during anti-tuberculosis (TB) chemotherapy. However, the
29 molecular composition and operation of the encoded “mycobacterial mutasome” – minimally
30 comprising DnaE2 polymerase and ImuA’ and ImuB accessory proteins – remain elusive. Following
31 exposure of mycobacteria to DNA damaging agents, we observe that DnaE2 and ImuB co-localize with
32 the DNA polymerase III β subunit (β clamp) in distinct intracellular foci. Notably, genetic inactivation
33 of the mutasome in an *imuB*^{AAAAGG} mutant containing a disrupted β clamp-binding motif abolishes
34 ImuB- β clamp focus formation, a phenotype recapitulated pharmacologically by treating bacilli with
35 griselimycin and in biochemical assays in which this β clamp-binding antibiotic collapses pre-formed
36 ImuB- β clamp complexes. These observations establish the essentiality of the ImuB- β clamp
37 interaction for mutagenic DNA repair in mycobacteria, identifying the mutasome as target for
38 adjunctive therapeutics designed to protect anti-TB drugs against emerging resistance.

39 INTRODUCTION

40 *Mycobacterium tuberculosis*, the causative agent of tuberculosis (TB), consistently ranks among the
41 leading infectious killers worldwide (WHO, 2021). The heavy burden imposed by TB on global public
42 health is exacerbated by the emergence and spread of drug-resistant (DR) *M. tuberculosis* strains,
43 with estimates indicating that DR-TB now accounts for approximately one-third of all deaths owing
44 to antimicrobial resistance (Hasan 2018). In the absence of a wholly protective vaccine, a continually
45 replenishing pipeline of novel chemotherapeutics is required (Evans and Mizrahi 2018) which, given
46 the realities of modern antibiotic development (Nielsen 2019), appears unsustainable. Therefore,
47 alternative approaches must be explored including the identification of effective multidrug
48 combinations (Cokol *et al.*, 2017), the elucidation of “resistance-proof” compounds (Ling 2015), and
49 the identification of so-called “anti-evolution” drugs that might limit the development of drug
50 resistance (Smith and Romesberg, 2007; Ragheb *et al.*, 2019; Merrikh and Kohli, 2020).

51 Whereas many bacterial pathogens accelerate their evolution by sampling the immediate
52 environment – for example, *via* fratricide, natural competence, or conjugation (von Wintersdorff *et*
53 *al.*, 2016; Veening and Blokesch, 2017) – these mechanisms appear inaccessible to *M. tuberculosis*:
54 the bacillus does not possess plasmids (Gray and Derbyshire, 2018) and there appears to be no role
55 for horizontal gene transfer in the modern evolution of strains of the *M. tuberculosis* complex
56 (Galagan, 2014; Boritsch and Brosch, 2016). Instead, genetic variation in *M. tuberculosis* results
57 exclusively from chromosomal rearrangements and mutations, a feature reflecting its ecological
58 isolation (an obligate pathogen, *M. tuberculosis* has no known host outside humans) and the natural
59 bottlenecks that occur during transmission (Gagneux, 2018). A question which therefore arises is
60 whether a specific molecular mechanism(s) drives *M. tuberculosis* mutagenesis – perhaps under
61 stressful conditions – and, consequently, if the activity thereof might be inhibited pharmacologically.

62 Multiple studies have investigated mycobacterial DNA replication and repair function in TB
63 infection models (for recent reviews, Singh, 2017; Minias *et al.*, 2018; Mittal *et al.*, 2020). From these,
64 the C-family DNA polymerase, DnaE2, has emerged as major contributor to mutagenesis under
65 antibiotic treatment (Boshoff *et al.*, 2003). A non-essential homolog of *E. coli* DNA Polymerase (Pol)
66 III α (Timinskas *et al.*, 2014), DnaE2 does not operate alone: the so-called “accessory factors”, *imuA'*
67 and *imuB*, are critical for DnaE2-dependent mutagenesis (Warner *et al.*, 2010) (**Figure 1A**). Both
68 proteins are of unknown function, however *imuA'* and *imuB* are upregulated together with *dnaE2*
69 following exposure of mycobacteria to DNA damaging agents including mitomycin C (MMC) (**Figure**
70 **1B**). This observation prompted the proposal that these three proteins might represent a


71 “mycobacterial mutasome” – named according to its functional analogy with the *E. coli* DNA Pol V
72 mutasome comprising UmuD’₂C-RecA-ATP (Jiang *et al.*, 2009; Erdem *et al.*, 2014).

73 Here, we apply live-cell fluorescence and time-lapse microscopy in characterizing a panel of
74 mycobacterial reporter strains expressing fluorescent translational fusions of each of the known
75 mutasome components. The results of these analyses, together with complementary *in vitro*
76 biochemical assays utilizing purified mycobacterial proteins, support the inference that ImuB serves
77 as a hub protein, interacting with the *dnaN*-encoded β clamp and ImuA’. They also reinforce the
78 essentiality of the ImuB- β clamp protein-protein interaction for mutasome function. Notably, while
79 a strong ImuA’-ImuB interaction is detected *in vitro*, we report live-cell data which indicate the
80 dispensability of either ImuA’ or DnaE2 for ImuB localization – but not mutasome function – in bacilli
81 exposed to genotoxic stress. Finally, using the β clamp-binding antibiotic, griselimycin (GRS) (Kling
82 *et al.*, 2015), we demonstrate in biochemical assays and in live mycobacteria the capacity to inhibit
83 mutasome function through the pharmacological disruption of ImuB- β focus formation. These
84 observations suggest that, through its inhibition of β clamp binding, GRS naturally limits the capacity
85 for induced mutagenesis. Therefore, as well as revealing a built-in mechanism protecting against
86 auto-induced mutations to GRS resistance, our results support the potential utility of “anti-evolution”
87 antibiotics for TB.

88 RESULTS

89 ImuB forms distinct sub-cellular foci under DNA damaging conditions.

90 Our previous genetic evidence (Warner *et al.*, 2010) informed a tentative model in which the
91 catalytically inactive Y family Pol homolog, ImuB, functioned as an adapter protein. According to the
92 model, DnaE2 gains access to the repair site by interacting with ImuB, which similarly interacts with
93 ImuA’ and the *dnaN*-encoded β clamp subunit (**Figure 1A**). To investigate the subcellular
94 localizations of each of the mutasome proteins in live bacilli, we constructed reporter alleles in which
95 the *M. smegmatis* mutasome proteins were labelled by N-terminal translational attachment of either
96 Enhanced Green (EGFP) or Venus Fluorescent Protein (VFP) tags (**Figure 1 – figure supplement 1A**).
97 The reporter alleles were introduced into each of three individual *M. smegmatis* mutasome gene
98 deletion mutants – $\Delta dnaE2$, $\Delta imuA'$, and $\Delta imuB$ (Warner *et al.*, 2010) – to yield the complemented
99 strains, $\Delta dnaE2$ *attB::egfp-dnaE2* (designated G-*dnaE2*), $\Delta imuB$ *attB::egfp-imuB* (G-*imuB*), and
100 $\Delta imuA'$ *attB::vfp-imuA'* (V-*imuA'*).



101
 102 **Figure 1. Components of the mycobacterial mutasome.** **A.** Cartoon summarizing the available genetic,
 103 microbiological and bioinformatic data (Boshoff et al., 2003; Warner et al., 2010; Timinskas and Venclovas,
 104 2019) into a working model of predicted mutasome composition. This model proposes that *ImuB* (blue)
 105 functions as an adapter protein, binding the *dnaN*-encoded β clamp (orange) to enable access of the error-
 106 prone *DnaE2* subunit (magenta) to the DNA replication fork. *ImuB* has also been predicted to bind
 107 accessory protein *ImuA'* (yellow). **B.** A volcano plot depicting transcriptional data from Müller et al. (2018)
 108 which were derived from RNA-seq analyses of wild-type *M. smegmatis* mc²155 exposed to 1×MIC
 109 Mitomycin C (MMC). Consistent with corresponding observations in *M. tuberculosis* (Boshoff et al., 2003;
 110 Warner et al., 2010), the mutasome components, *imuA'*, *imuB*, and *dnaE2* are among the 15 most highly
 111 upregulated mycobacterial genes following MMC exposure. **C.** Representative stills from single-cell time-
 112 lapse fluorescence microscopy experiments of *M. smegmatis* expressing translational reporters of the
 113 different mutasome components. Phase contrast and fluorescence images of *M. smegmatis* expressing G-
 114 *ImuB* and mCherry-*DnaN*, V-*ImuA'* and mCherry-*DnaN*, and G-*DnaE2* and mCherry-*DnaN* are represented
 115 following 4 h exposure to ½×MIC MMC. Scale bars in the overlay image represent 5 μ m. Inset images at
 116 the top right corner of the fluorescence and overlay images show a zoomed-in region corresponding to the
 117 yellow box in each phase contrast image (inset scale bar represents 2 μ m). The right-hand panel illustrates

118 *normalised fluorescence intensity along the longitudinal axis (as percentage [%] of the total cell length) of*
119 *a representative cell from each strain; the cell analysed is indicated by the blue dotted lines in the*
120 *corresponding phase contrast image. Single-cell time-lapse fluorescence microscopy experiments were*
121 *repeated 2-4 times; a typical experiment collected images from approximately 80 XY points.*

122 The mycobacterial DNA damage response was induced by exposing the strains to the natural
123 product antibiotic, mitomycin C (MMC), an alkylating agent that causes monofunctional DNA adducts
124 and inter-strand and intra-strand cross-links (Bargonetti *et al.*, 2010). Following exposure of *V-imuA'*
125 to MMC for 4 hours, a yellow fluorescence signal was observable throughout the cells (**Figure 1C,**
126 **Figure 1 – figure supplement 1B**), suggesting diffuse distribution of the VFP-ImuA' protein in the
127 mycobacterial cytoplasm. In contrast, distinct EGFP-ImuB foci were observed in *G-imuB* bacilli
128 following MMC treatment (**Figure 1C, Figure 1 – figure supplement 1B**). Although less distinct,
129 EGFP-DnaE2 produced similar evidence of focus formation in *G-dnaE2* cells (**Figure 1C, Figure 1 –**
130 **figure supplement 1B**). Notably, the significant increase in signal detectable in *V-imuA'*, *G-imuB*, and
131 *G-dnaE2* for MMC-exposed *versus* unexposed cells (**Figure 1 – figure supplement 1B**) confirmed that
132 expression of the respective fluorescence reporter alleles was DNA damage-dependent in all three
133 reporter mutants.

134 To determine whether these observations were also true for other types of DNA damage, the
135 three reporter mutants were subjected to ultra-violet (UV) light exposure. Equivalent fluorescence
136 phenotypes were observed for each of the three reporter alleles under both DNA damaging
137 treatments (**Figure 1 – figure supplement 1B**). As UV exposure causes cyclobutane pyrimidine
138 dimers or pyrimidine-pyrimidone (6-4) photoproducts (Boshoff *et al.*, 2003), while MMC generates
139 inter-strand DNA cross-links at CpG sites (Tomasz, 1995), these results indicated that expression and
140 localization (recruitment) of the mutasome components might be independent of the nature of the
141 genotoxic stress applied.

142 **N-terminal fluorescent reporters retain wild-type mutagenic function but are deficient in DNA** 143 **damage tolerance.**

144 The addition of bulky fluorescent tags can disrupt the function of DNA replication and repair proteins
145 (Renzette *et al.*, 2005). To determine whether any of the tagged mutasome proteins were affected,
146 the functionalities of the *egfp-imuB*, *vfp-imuA'* and *egfp-dnaE2* alleles were assessed in two standard
147 assays (Boshoff *et al.*, 2003; Warner *et al.*, 2010): the first investigated DNA damage-induced
148 mutagenesis following UV irradiation, and the second tested DNA damage tolerance following
149 treatment with MMC. As observed previously (Boshoff *et al.*, 2003; Warner *et al.*, 2010), exposure of
150 the wild-type parental *M. smegmatis* mc²155 to a sub-lethal dose of UV irradiation increased the
151 frequency of rifampicin (RIF) resistance 50- to 100-fold, as determined from enumeration of colony

152 forming units (CFU) on RIF-containing solid growth medium. In contrast, induced mutagenesis was
153 greatly reduced in the $\Delta imuA'$, $\Delta imuB$, and $\Delta dnaE2$ deletion mutants: mutation frequencies for these
154 “mutasome-deficient” strains were approximately 20-fold lower than wild-type (**Figure 1 – figure**
155 **supplement 2A**). Complementation with the cognate fluorescent reporter allele in $V-imuA'$, $G-imuB$
156 and $G-dnaE2$ restored the UV-induced mutation frequency of each of the three knockout mutants to
157 near wild-type levels, establishing that each of the fluorescence reporter alleles retained function in
158 UV-induced mutagenesis assays.

159 Surprisingly, the DNA damage tolerance assay – in which CFU forming ability is tested during
160 continuous exposure to MMC in solid medium – produced contrasting results (**Figure 1 – figure**
161 **supplement 2B**): unlike in the mutagenesis assay, complementation of either $imuA'$ or $imuB$ gene
162 deletion mutants with their corresponding fluorescent reporter alleles failed to restore the wild-type
163 phenotype, whereas $dnaE2$ hypersusceptibility was reversed. The reason for these discrepant
164 observations – restoration of UV-induced mutagenesis but not MMC-induced DNA damage tolerance
165 – in the $imuA$ and $imuB$ strains is not clear. It seems likely that the different types of DNA damage
166 induced by the two separate treatments might require distinct repair pathways and, potentially,
167 discrete protein interactions which were differentially disrupted by the presence of a fluorescent tag
168 on either mutasome component. Another possibility is that this phenotype was caused by the
169 persistent/recurring damage sustained by the bacilli throughout the 4-day incubation on MMC-
170 containing medium – dissimilar to the comparatively short duration of UV exposure. However, these
171 explanations are speculative and require further investigation.

172 **ImuB localizes with the *dnaN*-encoded β clamp following DNA damage.**


173 We previously inferred that a putative interaction between ImuB and the *dnaN*-encoded β clamp was
174 essential for mutasome function (Warner *et al.*, 2010). To investigate the predicted interaction of
175 ImuB and the β clamp in live bacilli, each of the three mutasome reporter alleles was introduced
176 separately into an *M. smegmatis* mutant encoding an mCherry-tagged β clamp, mCherry-DnaN (Santi
177 *et al.*, 2013). The mCherry-DnaN reporter was chosen as background strain owing to its previous
178 validation in single-cell time-lapse fluorescence microscopy analyses of *M. smegmatis* replisome
179 location (Santi *et al.*, 2013; Santi and McKinney, 2015). For the time-lapse experiments, the *M.*
180 *smegmatis* dual reporter strains were grown in standard 7H9/OADC medium for 12 hours, following
181 which the cells were exposed to MMC for 4.5 hours before switching back to 7H9/OADC for post-
182 treatment recovery (**Figure 1C; Figure 2; Videos 1-3**). At 4 hours post MMC treatment, distinct EGFP-
183 ImuB foci were observed (**Figure 1C panel i**) which, when overlaid with the mCherry-DnaN
184 fluorescence signal, showed considerable overlap, suggesting association of the β clamp with ImuB.

185 Notably, the EGFP-ImuB signal was almost exclusively detected in very close proximity to mCherry-
186 DnaN foci, with very rare instances of EGFP signal detectable in regions where fluorescence was
187 absent. This association was independent of the duration of MMC exposure, occurring at all time
188 points tested (**Figure 2A; Video 1**). In combination, these results support the direct physical
189 interaction of ImuB and the β clamp, as suggested previously by yeast two-hybrid and site-directed
190 mutagenesis studies (Warner *et al.*, 2010).

191 For V-ImuA', a diffuse fluorescence signal was detected throughout the cells (**Figure 1C panel**
192 **ii; Figure 2B; Video 2**), rendering impossible any conclusion about the potential recruitment of ImuA'
193 to β clamp (mCherry-DnaN) foci. In contrast, the results for DnaE2 were more nuanced: overlap of
194 peak fluorescence signals from EGFP-DnaE2 and mCherry-DnaN proteins was detected (**Figure 1C**
195 **panel iii; Figure 2C**) and was most evident within 1 hour post removal of MMC from the microfluidic
196 chamber (**Video 3**). Although not as consistent as the ImuB- β clamp phenotype, the co-localization
197 was reproducibly observed in multiple cells and across different experiments.

198 **ImuA' and DnaE2 are not required for ImuB focus formation.**

199 We showed previously that deletion of *imuA'* phenocopied abrogation of either *imuB* or
200 *dnaE2* in the MMC sensitivity assay (Warner, *et al.*, 2010) and, consistent with the interpretation that
201 all three components are individually essential for mutasome activity, this phenotype was not
202 exacerbated in a triple knockout mutant ($\Delta imuA' - imuB \Delta dnaE2$) lacking all three mutasome
203 components. Moreover, yeast two-hybrid results predicted a direct interaction between ImuB and
204 ImuA' (Warner *et al.*, 2010). Together, these observations suggested that a deficiency in ImuA' might
205 impair ImuB protein localization. To test this prediction, the *egfp-imuB* allele was introduced into the
206 $\Delta imuA'$ deletion mutant, generating a $\Delta imuA' attB::egfp-imuB$ reporter strain. Despite the loss of
207 ImuA' in this mutant, EGFP-ImuB foci were observed following MMC treatment (**Figure 2 - figure**
208 **supplement 1i**), mimicking the wild-type phenotype. The absence of functional DnaE2 similarly had
209 no discernible impact on ImuB focus formation in the corresponding catalytically dead *dnaE2^{ΔIA}*
210 *attB::egfp-imuB* or DnaE2-deleted $\Delta dnaE2 attB::egfp-imuB$, mutants (**Figure 2 - figure supplement**
211 **1ii & iii**). In combination, these results appear to eliminate a role for either ImuA' or DnaE2 in ImuB
212 localization, instead implying the critical importance of the ImuB- β clamp interaction for mutasome
213 function.



214

215

216

217

218

219

220

221

222

Figure 2. Representative time-lapse series of single-cells of *M. smegmatis* expressing the generated translational reporters in combination with mCherry-DnaN. A. G-ImuB (green) and mCherry-DnaN (magenta), B. V-ImuA' (green) and mCherry-DnaN (magenta), and C. G-DnaE2 (green) and mCherry-DnaN (magenta). Overlapping signals are viewed as white. The cells were exposed to MMC ($\frac{1}{2}$ ×MIC), from time 0 h until 4.5 h, after which the medium was switched back to standard 7H9 OADC medium. Up to 80 XY points were imaged at 10-minute intervals on fluorescence and phase channels for up to 36 h. The experiments were repeated 2–4 times. Numbers indicate hours elapsed. Scale bar represents 5 μ m. 7H9: Middlebrook 7H9 medium. MMC: Mitomycin C.


223 **Purified mutasome proteins interact in biochemical assays *in vitro*.**

224 All inference from this and previous work about the composition of the mycobacterial mutasome has
225 been derived from microbiological assays. To address this limitation, we expressed and purified
226 recombinant *M. smegmatis* mutasome proteins for biochemical analysis. Expression in *E. coli* of ImuB
227 alone yielded low quantities of soluble protein that was prone to degradation, while attempts to
228 express ImuA' alone failed to generate soluble protein. In contrast, co-expression of ImuB with ImuA'
229 yielded both proteins in a soluble form (**Figure 3**). Subsequently, the ImuA'B complex could be
230 captured *via* a histidine (His) affinity tag in ImuB. This confirmed that ImuA' and ImuB interact *in*
231 *vitro*, forming a stable complex even at protein concentrations as low as 400 nM (**Figure 3 – figure**
232 **supplement 1**), corroborating previous yeast two-hybrid results (Warner *et al.*, 2010). In *E. coli*,
233 overexpression of DnaE2 resulted in insoluble protein, while DnaE2 overexpression in *M. smegmatis*
234 appeared to be incompatible with cell viability: following transformation with the expression
235 construct, very few colonies were obtained and could not be expanded in liquid culture (not shown).

236 Next, we analysed the interaction of the *dnaN*-encoded β clamp with ImuB or the ImuA'B
237 complex (**Figure 3**). Samples of the *M. smegmatis* β clamp with ImuA'B (**Figure 3A panel i**) or ImuB
238 (**Figure 3A panel ii**), were injected onto an analytical size-exclusion chromatography column and
239 collected fractions were analysed by SDS-PAGE. Alone, the β clamp and ImuB/ImuA'B eluted at 1.47
240 and 1.55 ml, respectively. Incubation of the β clamp with either ImuB or ImuA'B caused a shift in the
241 retention volume to 1.36 ml, indicative of complex formation. This was confirmed by SDS-PAGE
242 analysis, which indicated co-elution of the β clamp with ImuB and ImuA'B.

243 **GFP-ImuB and VFP-ImuA' form a stable complex.**

244 Our microbiological assays had unexpectedly revealed discrepant complementation phenotypes for
245 UV exposure (**Figure 1 – figure supplement 2A**) *versus* MMC treatment (**Figure 1 – figure**
246 **supplement 2B**), raising the possibility that the fluorescent tags in the bioreporter mutants might
247 disrupt a protein-protein interaction(s) essential for DNA damage tolerance. We therefore
248 investigated the capacity of the fluorescently labelled EGFP-ImuB and VFP-ImuA' proteins to form a
249 stable complex. To this end, His-EGFP-ImuB was co-expressed with Strep-VFP-ImuA' in *E. coli* and
250 the complex analysed in three consecutive chromatography steps (**Figure 3 – figure supplement**
251 **1B**). First, the cell lysate was loaded onto a HisTrap column to capture the VFP-ImuA':EGFP-ImuB
252 complex via the His-tag present in EGFP-ImuB. Next, the elution fractions containing the complex
253 were loaded on a StrepTrap column to capture the complex via the strep-tag on VFP-ImuA'. Finally,
254 the VFP-ImuA':EGFP-ImuB complex was injected onto a size-exclusion column.



255
 256 **Figure 3. ImuB and ImuA'-ImuB interact with the DnaN and these interactions are disrupted by GRS.**
 257 **A.** Gel filtration profiles of *M. smegmatis* (i) ImuA'-ImuB-DnaN and (ii) ImuB-DnaN complexes in the
 258 absence or presence of 15 μ M GRS. For these experiments, 5 μ M DnaN was added to 10 μ M of (i) ImuA'-
 259 ImuB or (ii) ImuB. The gel filtration profiles of the individual proteins (ImuB and DnaN) or complex (ImuA'-
 260 ImuB) are shown for comparative purposes, and all curves were scaled for clarity. **B.** SDS-PAGE analysis
 261 of sequential fractions of the gel filtration runs. Gels are sorted in the same order as the corresponding gel
 262 filtration profiles shown in A.

263 During all purification steps, EGFP-ImuB with VFP-ImuA' were co-eluted as a complex, as indicated
264 by SDS-PAGE analysis and fluorescent detection of GFP-ImuB and VFP-ImuA' in the same elution
265 fractions. In combination, these observations suggest that the fluorescent tags did not disrupt ImuA'-
266 ImuB complex formation – a result which additionally implies that the absence in live cells of a clear
267 ImuA' (co-)localization phenotype was not a function of the tags.


268 **Inhibition of ImuB- β clamp binding eliminates focus formation.**

269 Previous work established that the β clamp-binding domain of ImuB was essential for mutasome
270 function: mutant strains carrying either a *imuB* ^{Δ C168} allele – which lacks the 168 amino acids in the
271 ImuB C-terminal region – or a *imuB*^{AAAAGG} allele – in which the wild-type β clamp-binding motif,
272 ³⁵²QLPLWG³⁵⁷, is substituted with the non-functional ³⁵²AAAAGG³⁵⁷ peptide sequence – phenocopied
273 full *imuB* deletion (Warner *et al.*, 2010). Therefore, to test the prediction that the SOS-regulated
274 recruitment of EGFP-ImuB and mCherry- β clamp into discernible foci was dependent on the ImuB- β
275 protein-protein interaction, we introduced an *egfp-imuB*^{AAAAGG} allele into the Δ *imuB* mutant. In
276 contrast to the wild-type reporter (*G-imuB*), the β clamp-binding motif mutant (*G-imuB*^{AAAAGG})
277 exhibited no EGFP foci in any cell imaged following exposure to MMC (**Figure 4A panel ii**). Instead,
278 the fluorescence was detectable throughout the cell as a diffuse signal (**Figure 4B**). This result
279 supports the inferred essentiality of the physical interaction between ImuB and β for ImuB
280 localization and, moreover, establishes that detection of ImuB- β foci provides a reliable visual proxy
281 for functional mutasome formation.

282 **Griselimycin blocks ImuB- β clamp binding, preventing focus formation in *M. smegmatis*.**

283 Griselimycin (GRS) is a natural product antibiotic that binds the mycobacterial β clamp with high
284 affinity, preventing DNA replication by blocking the essential interaction with the PolIII α subunit,
285 DnaE1 (Kling *et al.*, 2015). Notably, the location of GRS binding overlaps with the region predicted to
286 interact with other β clamp-binding proteins, including ImuB (Bunting *et al.*, 2003; Burnouf *et al.*,
287 2004; Kling *et al.*, 2015). Therefore, we hypothesized that GRS might disrupt the ImuB- β interaction.
288 Indeed, addition of GRS disrupted the *in vitro* interaction between the β clamp and pre-formed
289 ImuA'B complex (**Figure 3A panel i**) as well as between the β clamp and ImuB (**Figure 3A panel ii**),
290 as indicated by a gel filtration profile that is a superposition of the absorbance traces of the sample
291 individual components (β clamp and ImuB or β clamp and ImuA'B). This was confirmed by SDS-PAGE
292 analysis (**Figure 3B**). To confirm that the disrupting effect of GRS on the complex was the result of
293 the GRS- β clamp binding (Kling *et al.*, 2015), we measured the melting curves of the β clamp in the
294 presence and absence of GRS (**Figure 3 – figure supplement 1C**). Incubation with GRS led to a 3 °C

295 increase in the protein melting temperature, consistent with GRS binding to β . In contrast, no effect
 296 of GRS was observed on the melting temperatures of ImuA'B.



297

298 **Figure 4. Disrupting the DnaN-ImuB interaction.** **A.** Representative images of *G-imuB* exposed to 2 \times
 299 MIC MMC for 4 hr (top panel) or 2 \times MIC MMC and GRS for 4 hr (centre panel) and *G-imuB^{AAAAGG}* mutant
 300 exposed to 2 \times MIC MMC for 4 hr (bottom panel). Scale bars represent 5 μm . **B.** Cells aligned by mid-cell
 301 position, arranged according to cell length and coloured (white to red) according to fluorescence intensity
 302 showing the presence of *G-ImuB* foci following MMC treatment and the lack thereof after GRS exposure.
 303 *G-imuB^{AAAAGG}* shows no foci, similar to the *G-imuB* strain following GRS exposure. **C.** Super-resolution
 304 imaging confirms disruption of *ImuB*- β clamp foci in mycobacteria treated with GRS. Representative iPALM
 305 localizations of PC-*ImuB* bacilli exposed to (top) 5 \times MIC MMC or (bottom) 5 \times MIC GRS. Subdiffraction-
 306 limited super-resolution localization of PC-*ImuB* is observed as highly dense localizations of signal following
 307 exposure to MMC; in contrast, GRS prevents the formation of high-density localizations. Scale bars are 1
 308 μm and 2 μm in the top and bottom micrographs, respectively; molecule probability represents the
 309 fluorescence localization probability from minimum (black) to maximum (white) likelihood.

310 Next, we examined whether these *in vitro* observations were recapitulated in live
311 mycobacterial cells. To this end, the *G-imuB* strain was exposed to MMC (**Figure 4A panel i**) or MMC
312 plus GRS (**Figure 4A panel iii**). Notably, the addition of GRS in combination with MMC abrogated *G-*
313 *imuB* focus formation, phenocopying the diffuse fluorescence distribution observed following
314 exposure of the β clamp-binding deficient GFP-ImuB^{AAAAGG} mutant to MMC **Figure 4A panel ii**).
315 Population analyses of these data confirmed that GRS blocked ImuB focus formation in MMC-exposed
316 cells (**Figure 4B**), suggesting the potential for chemical disruption of mutasome function.

317 **Super-resolution microscopy confirms GRS elimination of ImuB- β foci in *M. smegmatis*.**

318 Finally, to examine the inferred disruption of ImuB focus formation by single-molecule microscopy,
319 we generated an additional reporter mutant in which ImuB was N-terminally labeled with the
320 photoconvertible, fixation-resistant mEos4a fluorophore (Paez Segala *et al.*, 2015). The resulting PC-
321 *imuB* strain was imaged in 3D by iPALM (Shtengel *et al.*, 2009) following exposure to MMC or GRS
322 (**Figure 4C**). Consistent with the epifluorescence data, bacilli exposed to MMC were characterized by
323 a region of high-density PC-ImuB localizations (**Figure 4C top panel**). In contrast, exposure to GRS –
324 which on its own has been shown to induce the *M. smegmatis* SOS response (Kling *et al.*, 2015) – did
325 not elicit high molecule densities: instead, a low-density of molecules was detected throughout the
326 interior of the cell, reinforcing the inferred absence of ImuB recruitment in GRS-exposed cells (**Figure**
327 **4C bottom panel**).

328 **DISCUSSION**

329 In *E. coli*, the DNA damage-induced SOS response triggers overexpression of *umuC*, *umuD* and *recA*
330 (Maslowska *et al.*, 2019). UmuC is an error prone Y-family DNA polymerase that requires the binding
331 of UmuD₂ and RecA to reach full activity and this “mutasome”, collectively referred to as PolV, has
332 been implicated in DNA damage tolerance and induced mutagenesis (Goodman *et al.*, 2016). At the
333 onset of the work reported here, genetic evidence from diverse bacteria lacking PolV supported the
334 co-dependent operation of ImuA, ImuB, and DnaE2 in the LexA-regulated SOS response, suggesting
335 these proteins might function in an analogous manner (McHenry, 2011; Ippoliti *et al.*, 2012). In
336 mycobacteria, in which they have also been implicated in DNA damage tolerance and induced
337 mutagenesis (Boshoff and Mizrahi, 2000; Warner *et al.*, 2010), the non-homologous ImuA' replaces
338 ImuA, nevertheless the inferred universal model for mutasome function in bacteria lacking an *E. coli*
339 PolV homolog was the same (Timinskas and Venclovas, 2019): the catalytically inactive Y family
340 polymerase, ImuB, functions as hub protein, interacting physically with the β clamp via a defined β
341 clamp-binding motif and with DnaE2 and ImuA' (or ImuA) via unknown mechanisms which might

342 include the disordered ImuB C-terminal region or sub-regions thereof, including the RecA-NT motif
343 (Timinskas and Venclovas, 2019). However, the absence of any direct biochemical and/or structural
344 evidence to support the proposed protein interactions meant this assumption was speculative.
345 Moreover, whereas *E. coli* PolV is known to be subject to multiple forms of regulation – including
346 temporal (Robinson *et al.*, 2015), spatial (Robinson *et al.*, 2015), internal (Erdem *et al.*, 2014) and
347 conformational (Jiang *et al.*, 2009; Gruber *et al.*, 2015; Jaszczur *et al.*, 2019) – the expression dynamics
348 and sub-cellular localizations of the mycobacterial mutasome proteins were mostly unknown.

349 By fluorescently tagging the known mutasome proteins, we have observed in real-time the
350 consistent formation of co-localizing ImuB- β clamp foci in mycobacterial cell populations exposed to
351 genotoxic stress. Although less pronounced than ImuB, we also detected the frequent, reproducible
352 co-localization of DnaE2 with the β clamp under the same conditions. Notably, recruitment of ImuB
353 into foci occurred in mutants lacking either *dnaE2* or *imuA'* but was prevented where the ImuB β
354 clamp-binding motif was mutated – apparently identifying the primacy of the ImuB- β clamp
355 interaction in mutasome organization. In contrast, the function(s) and sub-cellular dynamics of
356 ImuA' remain enigmatic: VFP-ImuA' consistently produced diffuse fluorescence in DNA-damaged
357 bacilli, precluding any definitive insights into its potential association with ImuB (or DnaE2) *in vivo*.
358 We did, however, observe co-elution of ImuA'-ImuB and ImuA'-ImuB- β clamp complexes *in vitro*,
359 results which provided important biochemical confirmation of the inferred interaction of ImuA' and
360 ImuB predicted previously (Warner *et al.*, 2010). While difficult to reconcile with these data, the
361 absence of a clear co-localization signal in live cells might indicate the transient association of ImuA'
362 with its mutasome partners, or possibly a modification analogous to the proteolytic cleavage of UmuD
363 to UmuD' in the *E. coli* SOS response (Goodman *et al.*, 2016). Future work will require single-molecule
364 tracking of ImuA' to resolve this possibility.

365 The original identification of the *imuA-imuB-dnaE2* cassette noted its close association with
366 LexA across diverse bacteria; that is, genomes containing the cassette invariably encoded a LexA
367 homolog, too (Erill *et al.*, 2006). Recent work in mycobacteria has, however, added unexpected
368 nuance to that regulatory framework, namely that the split *imuA'-imuB/dnaE2* cassette is subject to
369 transcriptional control by both the “classic” LexA/RecA-regulated SOS response and the PafBC-
370 mediated DNA damage response. The authors also report that, while the two regulatory mechanisms
371 are partially redundant for genotoxic stresses including UV and MMC exposure, fluoroquinolones
372 appear to be specific inducers of PafBC only (Adefisayo *et al.*, 2021). In addition to suggesting that
373 chromosomal mutagenesis is co-dependent on PafBC and SOS, these observations are important in
374 identifying an apparent “fail-safe” mechanism in mycobacteria in which the mutasome components

375 are induced irrespective of DNA damage type – again reinforcing the centrality of these proteins in
376 damage tolerance and, by implication, adaptive mutagenesis.

377 We previously observed that the *imuB*^{AAAAGG} β clamp-binding mutation eliminated UV-
378 induced mutagenesis and MMC damage tolerance in *M. smegmatis* (Warner *et al.*, 2010),
379 phenocopying deletion of any of the three mutasome components (*imuA'*, *imuB*, *dnaE2*) alone or in
380 combination. Given the abrogation of ImuB focus formation, it is reasonable to infer a direct link
381 between ImuB- β clamp focus formation and mutasome function. In turn, this suggests that blockade
382 of ImuB focus formation might offer a tractable read-out for a screen designed to identify mutasome
383 inhibitors – a possibility reinforced by the observed co-elution in biochemical assays of β with ImuB
384 and, separately, of the β clamp with pre-formed ImuA'-ImuB complexes. In this context, it was notable
385 in the current work that GRS disrupted the ImuB- β clamp interaction *in vitro* and prevented ImuB
386 focus formation in mycobacteria treated simultaneously with MMC and GRS.

387 The discrepant complementation phenotypes observed for V-*imuA'* and G-*imuB* in the DNA
388 damage tolerance (MMC treatment) *versus* induced mutagenesis (UV exposure) assays suggests that
389 addition of the bulky fluorophore might have prevented full function of these mutasome proteins.
390 Whereas UV irradiation predominantly generates cyclobutane dimers and pyrimidine-pyrimidone
391 (6–4) photoproducts (Franklin *et al.*, 1985), MMC induces different DNA lesions, including inter- and
392 intra-strand crosslinks. These are likely to require multiple repair proteins and, potentially, the
393 interaction of mutasome components with additional proteins – which might be prevented by the
394 bulky fluorescent tags. The DnaE2-EGFP fusion proved the exception; in this context, it might be
395 instructive to consider recent evidence implicating DnaE2 in gap filling following nucleotide excision
396 repair in non-replicating *Caulobacter crescentus* cells (Joseph *et al.*, 2021). These observations
397 suggest the importance of identifying other potential interacting partners of mycobacterial DnaE2
398 (and the other mutasome components), work which is currently underway in our laboratory.

399 The potential for inhibitors of DNA replication to accelerate the development of genetic
400 resistance through the induction of mutagenic repair pathways (Cirz *et al.*, 2005; Barrett *et al.*, 2019;
401 Revitt-Mills and Robinson, 2020) is a valid and commonly cited concern that might partially explain
402 the relative under-exploration of DNA metabolism as source of new antibacterial drug targets
403 (Reiche *et al.*, 2017; van Eijk *et al.*, 2017). Our results suggest that GRS could offer an interesting
404 exception: that is, in binding the β clamp at the site of interaction with the DnaE1 replicative DNA
405 polymerase (Kling *et al.*, 2015) as well as other DNA metabolizing proteins, including ImuB, GRS
406 appears to possess an intrinsic protective mechanism against induced mutagenesis – blocking both
407 ImuB-dependent mutasome recruitment to stalled replisomes and post-repair fixation of mutations

408 by the replicative polymerase, DnaE1. This “resistance-proofing” capacity, which is supported by the
409 reported restriction of GRS resistance to low-frequency, high-fitness cost amplifications of the *dnaN*
410 genomic region with very few to no “off-target” SNPs, might also contribute to the observed
411 bactericidal effect of GRS against mycobacteria (Kling *et al.*, 2015). In addition, it reinforces the β
412 clamp as vulnerable target for new TB drug development (Bosch *et al.*, 2021). In this context, it is
413 worth noting that inhibition of DnaE1 replicative polymerase function might represent a general
414 solution to the problem of drug-induced (auto)mutagenesis by preventing fixation of
415 repair/tolerance-generated mutations; in support of this inference, another natural product,
416 nargenicin, which inhibits *Mtb* DnaE1 via a DNA-dependent mechanism, fails to yield spontaneous
417 resistance mutations *in vitro* (Chengalroyen *et al.*, 2021). Therefore, while the essentiality of DNA
418 replication proteins (including DnaN, DnaE1) for mycobacterial viability poses a challenge to the
419 design of assays of “anti-evolution” compounds targeting these proteins, GRS (and nargenicin)
420 appear to provide compelling evidence that precise inhibition of specific DNA replicative and repair
421 functions might ameliorate the perceived risks in targeting this area of mycobacterial metabolism.

422 As an obligate human pathogen, persistence of *M. tuberculosis* within its host depends on the
423 ability to drive successive cycles of infection, disease – in some cases latency followed by reactivation
424 disease – and transmission (Lin and Flynn, 2018). This process is necessarily vulnerable to multiple
425 potential evolutionary culs-de-sac which might arise in consequence of the elimination of the bacillus
426 by the host (clearance) or the demise of the organism within the infected individual (controlled
427 subclinical infection, or host death). Modern *M. tuberculosis* strains therefore represent the
428 genotypes that have successfully adapted to human colonization (Gagneux, 2018), evolving with their
429 obligate host through changes in lifestyle and nutritional habits (with their associated implications
430 for non-communicable diseases such as diabetes), the near-universal administration of the BCG
431 vaccination, the emergence of the HIV co-pandemic, and the widespread use of frontline combination
432 chemotherapy (Warner *et al.*, 2015). While the emergence and propagation of drug-resistant isolates
433 characterized by a variety of polymorphisms at multiple genomic loci (Warner *et al.*, 2017; Farhat *et al.*,
434 2019; Payne *et al.*, 2019) provides strongest proof of the capacity for genetic variation in *M.*
435 *tuberculosis*, other lines of evidence include the highly subdivided population structure of the *M.*
436 *tuberculosis* Complex (Riojas *et al.*, 2018), the well-described geographical host-pathogen sympatry
437 (Hershberg *et al.*, 2008; Brynildsrud *et al.*, 2018) and, more recently, the observation of intra-patient
438 bacillary microdiversity (Ley *et al.*, 2019). In combination, these elements support the ongoing
439 evolution of *M. tuberculosis*, as well as suggest the potential that “anti-evolution” therapeutics might
440 yield much greater benefit in the clinical context than can be inferred from *in vitro* studies – in which

441 the pressures on an obligate pathogen can only be approximated. That is, in addition to identifying
442 the mutasome as target for adjunctive therapeutics designed to protect anti-TB drugs against
443 emergent resistance, the results presented here support the further exploration of this and related
444 strategies to disarm host-adaptive mechanisms in a major human pathogen.

445 **MATERIALS AND METHODS**

446 **Bacterial strains and culture conditions**

447 All mycobacterial strains (**Supplementary File 2 – Key Reagents**) were grown in liquid culture
448 containing Difco™ Middlebrook 7H9 Broth (BD Biosciences, San Jose, CA) and supplemented with 0.2
449 % (v/v) glycerol (Sigma Aldrich, St. Louis, MO), 0.005 % (v/v) Tween® 80 (Sigma Aldrich, St. Louis,
450 MO), and 10 % (v/v) BBL™ Middlebrook OADC Enrichment (BD Biosciences, San Jose, CA). For *M.*
451 *smegmatis*, liquid cultures were incubated at 37 °C with orbital shaking at 100 rpm, until the desired
452 growth density was attained – measured by spectrophotometry at a wavelength of 600 nm – before
453 further experimentation. Solid media comprised Difco™ Middlebrook 7H10 Agar (BD Biosciences,
454 San Jose, CA) supplemented with 0.5 % (v/v) glycerol (Sigma Aldrich, St. Louis, MO), and 10 % (v/v)
455 BBL™ Middlebrook OADC Enrichment (BD Biosciences, San Jose, CA). Solid media plates were
456 incubated at 37 °C for 3–4 days or until colonies had formed.

457 **Mutasome reporter constructs**

458 The *V-imuA'* construct was designed by altering the coding sequence of *imuA'* within the
459 complementing vector, pAINT::*imuA'* (Warner *et al.*, 2010), so that the coding sequence of Venus
460 fluorescent protein (VFP) (Nagai *et al.*, 2002) was inserted in-frame after the start codon of the *imuA'*
461 ORF. Furthermore, an in-frame FLAG tag sequence (Einhauer and Jungbauer, 2001) was inserted
462 between the coding region of *vfp* and *imuA'* to produce a single ORF encoding VFP-FLAG-ImuA'. For
463 ImuB, the construct PSOS(*imuA'*)-*egfp-imuB* was designed such that the regulatory elements
464 immediately upstream of *imuA'* were inserted immediately upstream of the *imuB* ORF which was
465 further altered by inserting the sequence encoding EGFP (Cormack *et al.*, 1996) linked to a FLAG tag-
466 encoded sequence immediately after the start codon of *imuB* to produce a single ORF encoding EGFP-
467 FLAG-ImuB' which was cloned into pMCAINT::*imuB* (Warner *et al.*, 2010). The photoconvertible
468 PSOS(*imuA'*)-*mEos4A-imuB* construct was based on the *G-imuB* construct, such that the coding
469 sequence of EGFP was replaced by mEos4a (Paez Segala *et al.*, 2015), yielding mEos4A-FLAG-ImuB.
470 For DnaE2, the *egfp* sequence was inserted in-frame after the start codon of *M. smegmatis dnaE2*.

471 **Mutant binding G-*imuB*^{AAAAGG} construct**

472 To introduce the ³⁵²AAAAGG³⁵⁷ ImuB allele (Warner *et al.*, 2010) into the EGFP-ImuB protein, the
473 nucleotide sequence from pMCAINT::*imuB*^{AAAAGG} was swapped into the corresponding position of
474 PSOS(*imuA*'-)*egfp-imuB* to yield pMCAINT::PSOS(*imuA*'-)*egfp-imuB*^{AAAAGG}.

475 ***M. smegmatis* mutasome reporter strains**

476 *M. smegmatis* strain V-*imuA*' was generated by introducing the pAINT::*vfp-imuA*' plasmid into Δ *imuA*'
477 (Warner *et al.*, 2010) by the standard electroporation method. Strains G-*imuB*, PC-*imuB*, and G-
478 *imuB*^{AAAAGG} were developed by integration of the pMCAINT::PSOS(*imuA*'-)*egfp-imuB*,
479 pMCAINT::PSOS(*imuA*'-)*mEos4a-imuB*, or pMCAINT::PSOS(*imuA*'-)*egfp-imuB*^{AAAAGG} plasmid,
480 respectively, into the genome of Δ *imuB* (Warner *et al.*, 2010). The *dnaN-mCherry::G-imuB* strain was
481 developed by the electroporation of pMCAINT::PSOS(*imuA*'-)*egfp-imuB* into the *M. smegmatis dnaN-*
482 *mCherry* background (Santi *et al.*, 2013). To generate the G-*dnaE2* strain, pTweety::*egfp-dnaE2* was
483 electroporated into Δ *dnaE2* (Warner *et al.*, 2010). Similarly, *dnaN-mCherry::G-dnaE2* was generated
484 by electroporation of pTweety::*egfp-dnaE2* into *M. smegmatis dnaN-mCherry*. Mutasome-deficient
485 strains Δ *imuA*', Δ *dnaE2*, and *dnaE2*^{AIA} were electroporated with pMCAINT::PSOS(*imuA*'-)*egfp-imuB*
486 to produce Δ *imuA*'::*G-imuB*, Δ *dnaE2*::*G-imuB*, and *dnaE2*^{AIA}::*G-imuB*, respectively.

487 **Mutagenesis Assays**

488 Mutagenesis assays were performed as previously described (Boshoff *et al.*, 2003; Warner *et al.*,
489 2010), with RIF-resistant colonies enumerated on solid media after 5 days of growth. Mutation
490 frequencies were calculated by dividing the number of RIF-resistant colonies of each sample by the
491 CFU/ml of un-irradiated sample.

492 **Antibiotic treatments**

493 MMC (Mitomycin C from *Streptomyces caespitosus*) (Sigma Aldrich, St. Louis, MO) was dissolved in
494 ddH₂O, while GRS was dissolved in DMSO. Cultures of *M. smegmatis* were grown in 7H9-OADC—
495 supplemented with selection antibiotic where applicable—at 37 °C to an optical density (OD₆₀₀) of
496 between 0.2 and 0.4. Thereafter, cultures were split into different 5 ml cultures and MMC and/or GRS
497 was added to a final concentration dependent on the MIC (Kling *et al.*, 2015).

498 **Snapshot microscopy**

499 Single snapshot micrographs of *M. smegmatis* cells were captured with a Zeiss Axioskop M, Zeiss
500 Axio.Scope, and Zeiss Axio.Observer Z1. Briefly, 2.0–5.0 μ l of liquid culture was placed between a No.
501 1.5 glass coverslip and microscope slide. A transmitted mercury lamp light was used together with
502 filter cubes to visualize fluorescence using a 100 \times 1.4 NA plan apochromatic oil immersion objective
503 lens. Samples were located using either transmitted light, differential interference contrast (DIC), or
504 epifluorescence. Snapshot images were captured with either a Zeiss 1 MP or Zeiss AxioCam HRm

505 monochrome camera. Images of the same experiment were captured with the same instrument and
506 exposure settings. Green fluorescence of EGFP was detected using the Zeiss Filter Set 38 HE. Red
507 fluorescence of mCherry was detected using the Zeiss Filter Set 43. Images were captured using
508 AxioVision 4.7 or ZEN Blue Microscope and Imaging Software. Images were processed using Fiji
509 (Schindelin *et al.*, 2012); images of the same strain were contrasted to the same maximum and
510 minimum within an experiment.

511 **Quantitative image analysis**

512 *M. smegmatis* bacilli were plotted from shortest to longest and aligned according to their midcell
513 position (0 on the y axis) using the MicrobeJ plugin of ImageJ (Ducret *et al.*, 2016). Along each point
514 of the cell, a dot was generated and coloured according to the fluorescence intensity along the medial
515 axis of the bacillus. Therefore, this plot represents the fluorescence intensity along the medial axis of
516 every bacillus imaged under the relevant experimental conditions. R was used for visual
517 representation of the data.

518 **Super-resolution iPALM microscopy**

519 Three-dimensional PALM was performed using the iPALM instrument (Shtengel *et al.*, 2009). Round
520 25 mm diameter No. 1.5 coverslips were cleaned by sonication in 1 M KOH for 45 minutes. Following
521 rinsing in deionized water and drying at 60 °C, coverslips were coated with 5mg/ml >70,000
522 molecular weight poly-L-lysine hydrobromide (MP Biomedicals, Santa Ana, CA) for 30 minutes at
523 room temperature. Thereafter, gold nanorods were adhered to the coverslips for 30 minutes before
524 drying by vacuum centrifugation. Thin film deposition was used to coat the fiducial coverslips with
525 SiO₂. Thereafter, the fiducial coverslips were cleaned with 1 M KOH and coated with 1% poly-L-lysine
526 for 60 minutes at 37.0 °C. Bacterial cultures of OD₆₀₀ = 0.4 were exposed to drug conditions (5× MMC
527 or GRS) for 6 h before 3.0 ml of bacterial sample was centrifuged onto a fiducial coverslip at 3,200 rcf
528 for 15 minutes in a six-well plate. The sample was rinsed three times in Dulbecco's PBS and fixed
529 with 0.5% paraformaldehyde for 2 minutes. Thereafter, the sample was mounted in Dulbecco's PBS
530 and the gold coverslip were adhered to a clean (as above) 18mm diameter No. 1.5 round coverslip.
531 Each coverslip was sealed to prevent evaporation. The sample was mounted between two opposing
532 Nikon 60× 1.49 NA Apo TIRF oil immersion lenses and captured using three Andor iXon-3 EMCCD
533 cameras. Bacterial cells were located by DIC visualization, and each sample was imaged three times
534 at separate regions containing 2–5 bacilli using TIRF illumination. Experiments were repeated at
535 least three times. A calibration image of 100 cycles was taken of the gold fiducials in each field-of-
536 view. Bacilli were imaged for 25,000 cycles using alternating 405 nm (mEos4a photoconversion) and
537 561 nm (converted mEos4a excitation) laser cycles per frame. FF01-593/40 emission filters

538 (Semrock) were used during mEos4a imaging. Thereafter, the calibration file was processed using
539 PeakSelector™ (Shtengel *et al.*, 2009) and used to calibrate the detected localizations. During image
540 processing, low confidence localizations were excluded based on unwrapped Z-error and Z-position.
541 Images were produced with PeakSelector™.

542 **Single-cell time-lapse fluorescence microscopy**

543 Liquid cultures of *M. smegmatis* reporter strains were grown to mid-logarithmic phase ($OD_{600} = 0.6$),
544 cells were collected by centrifugation at $3900 \times g$ for 5 min and concentrated 10-fold in 7H9 medium.
545 The cells were filtered through a polyvinylidene difluoride (PVDF) syringe filter (Millipore) with a 5
546 μm pore size to yield a clump-free cell suspension. The single cell suspension was spread on a semi-
547 permeable membrane and secured between a glass coverslip and the *serpentine 2 chip* (Delincé *et al.*,
548 2016) in a custom-made PMMA/Aluminium holder (Dhar and Manina, 2015). Time-lapse microscopy
549 employing a DeltaVision personalDV inverted fluorescence microscope (Applied Precision, WA) with
550 a 100x oil immersion objective was used to image single cells of *M. smegmatis*. The bacteria and
551 microfluidic chip were maintained at 37 °C in an environmental chamber with a continuous flow of
552 7H9 medium, with or without 100 ng/ml of MMC, at a constant flow rate of $25 \mu\text{l}\cdot\text{min}^{-1}$, as described
553 previously (Wakamoto *et al.*, 2013; Dhar and Manina, 2015). Images were obtained every 10 min on
554 phase-contrast and fluorescence channels (for EGFP, excitation filter 470/40 nm, emission filter
555 525/50 nm; for mCherry, excitation filter 572/35, emission filter 632/60; for YFP excitation filter
556 500/20 nm, emission filter 535/30 nm) using a CoolSnap HQ2 camera. Image-based autofocus was
557 performed on each point prior to image acquisition. Experiments were repeated 2–4 times; a typical
558 experiment collected images from up to 80 XY points at the 10 min intervals. The images were
559 analysed using Fiji (Schindelin *et al.*, 2012).

560 **Protein expression and purification**

561 N-terminally His-tagged *M. smegmatis* ImuB was co-expressed with ImuA' in *E. coli* BL21(DE3) cells
562 using two expression vectors from the NKI-LIC vector suite (Luna-Vargas *et al.*, 2011): pETNKI-his-
563 3C-LIC-kan for ImuB and pCDFNKI-StrepII3C-LIC-strep for ImuA' that have different resistance
564 markers, kanamycin and streptomycin; as well as different origins of replication, ColE1 and CloDF13,
565 respectively. Protein production was induced with isopropyl 1-thio- β -d-galactopyranoside (IPTG) at
566 30°C for 2 hours. The ImuBA' complex was purified using a Histrap column followed by a Superdex
567 200 16/60 column. Both N-His6 *M. smegmatis* ImuB and β clamp were expressed in *E. coli* BL21(DE3)
568 cells and purified using HisTrap, HiTrap Q, and S200 columns. All proteins were flash frozen in liquid
569 nitrogen and stored at -80 °C.

570 **Size-exclusion chromatography analysis**

571 Samples of individual proteins and the different complexes were injected onto a PC3.2/30 (2.4 ml)
572 Superdex 200 Increase gel filtration column (GE Healthcare) pre-equilibrated in 50 mM Tris pH 8.5
573 and 300 mM NaCl. Thereafter, 50 μ l fractions were collected and analyzed by SDS-PAGE
574 electrophoresis using 4–12% NuPage Bis-Tris precast gels (Life Technologies). Gels were stained
575 with 0.01% (v/v) 2,2,2-Trichloroethanol (TCE) and imaged with UV light.

576 **Thermal unfolding experiments**

577 Melting curves of the *M. smegmatis* β clamp (5 μ M) in the presence and absence of GRS (15 μ M) were
578 measured in UV-capillaries using the Tycho NT6 (NanoTemper Technologies) where the protein
579 unfolding is followed by detecting the fluorescence of intrinsic tryptophan and tyrosine residues at
580 both emission wavelengths of 350 nm and 330 nm.

581 **ACKNOWLEDGMENTS**

582 This work was supported by the US National Institute of Child Health and Human Development
583 (NICHD) U01HD085531 (to D.F.W. and R.W.). We acknowledge the funding support of the Research
584 Council of Norway (R&D Project 261669 “Reversing antimicrobial resistance”) (to D.F.W.), the South
585 African Medical Research Council (to V.M. and D.F.W.); the National Research Foundation of South
586 Africa (to D.F.W. and V.M.); a Senior International Research Scholars grant from the Howard Hughes
587 Medical Institute (to V.M.); and a LUMC Fellowship (to M.H.L.). In addition, M.A.R. is grateful to the
588 South African National Research Foundation (NRF) for financial assistance during his PhD training
589 (grant no. 104683) as well as the Whitehead Scientific Travel Award. Z.A.M is grateful to the
590 University of Cape Town, the David and Elaine Potter Foundation Research Fellowship, and the Swiss
591 Government Excellence Research Scholarship for financial assistance during her PhD.

592 **SUPPLEMENTARY DATA**

593 **Supplementary File 1 – Supplementary figures**

594 **Supplementary File 2 – Key reagents**

595 **Video 1 – Time-lapse microscopy of G-ImuB and mCherry-DnaN dual reporter.** Representative
596 time-lapse movie of the reporter strain expressing G-ImuB and mCherry-DnaN. Bacteria were imaged
597 on fluorescence and phase channels for up to 36 hours at 10-minute intervals. Treatment with MMC
598 (100 ng/ml) was at 0 – 4.5 hours. This experiment was repeated 6 times. Numbers indicate the hours
599 (h) elapsed in the time-lapse experiment. 7H9, Middlebrook 7H9/OADC. MMC, Mitomycin C. Scale
600 bar, 5 μ m. G-ImuB, green; mCherry-DnaN, magenta; overlay, white.

601 **Video 2 – Time-lapse microscopy of V-ImuA' and mCherry-DnaN dual reporter.** Representative
602 time-lapse movie of the reporter strain expressing V-ImuA' and mCherry-DnaN. Bacteria were
603 imaged on fluorescence and phase channels for up to 36 hours at 10-minute intervals. Treatment
604 with MMC (100 ng/ml) was at 0 – 4.5 hours. This experiment was repeated 3 times. Numbers indicate
605 the hours (h) elapsed in the time-lapse experiment. 7H9, Middlebrook 7H9/OADC. MMC, Mitomycin
606 C. Scale bar, 5 μ m. V-ImuA', green; mCherry-DnaN, magenta; overlay, white.

607 **Video 3 – Time-lapse microscopy of G-DnaE2 and mCherry-DnaN dual reporter.** Representative
608 time-lapse movie of the reporter strain expressing G-DnaE2 and mCherry-DnaN. Bacteria were
609 imaged on fluorescence and phase channels for up to 36 hours at 10-minute intervals. Treatment
610 with MMC (100 ng/ml) was at 0 – 4.5 hours. This experiment was repeated 3 times. Numbers indicate
611 the hours (h) elapsed in the time-lapse experiment. 7H9, Middlebrook 7H9/OADC. MMC, Mitomycin
612 C. Scale bar, 5 μ m. G-DnaE2, green; mCherry-DnaN, magenta; overlay, white.

613 REFERENCES

- 614 Adefisayo, O.O., Dupuy, P., Bean, J.M. and Glickman, M.S. (2021). Division of labor between SOS and
615 PafBC in mycobacterial DNA repair and mutagenesis. *bioRxiv*, p. 2021.08.05.455301.
616 doi:10.1101/2021.08.05.455301.
- 617 Bargonetti, J., Champeil, E. and Tomasz, M. (2010). Differential toxicity of DNA adducts of mitomycin
618 C. *Journal of Nucleic Acids*, 698960. doi:10.4061/2010/698960.
- 619 Barrett, T.C., Mok, W.W.K.K., Murawski, A.M. and Brynildsen, M.P. (2019). Enhanced antibiotic
620 resistance development from fluoroquinolone persists after a single exposure to antibiotic.
621 *Nature Communications*, 10(1), pp. 1–11. doi:10.1038/s41467-019-09058-4.
- 622 Boritsch, E.C. and Brosch, R. (2016). Evolution of *Mycobacterium tuberculosis*: New insights into
623 pathogenicity and drug resistance. *Microbiology Spectrum*, (5), pp. 495–515.
624 doi:10.1128/9781555819569.ch22.
- 625 Bosch, B., DeJesus, M.A., Poulton, N.C., Zhang, W., Engelhart, C.A., Zaveri, A., Lavalette, S., Ruecker, N.,
626 Trujillo, C., Wallach, J.B., Li, S., Ehrt, S., Chait, B.T., Schnappinger, D. and Rock, J.M. (2021).
627 Genome-wide gene expression tuning reveals diverse vulnerabilities of *M. tuberculosis*. *Cell*,
628 184(17), pp. 4579–4592.e24. doi:10.1016/J.CELL.2021.06.033.
- 629 Boshoff, H.I. and Mizrahi, V. (2000). Expression of *Mycobacterium smegmatis* pyrazinamidase in
630 *Mycobacterium tuberculosis* confers hypersensitivity to pyrazinamide and related amides.
631 *Journal of Bacteriology*, 182(19), pp. 5479–85. doi:10.1128/JB.182.19.5479-5485.2000.

- 632 Boshoff, H.I.M.M., Reed, M.B., Barry, C.E. and Mizrahi, V. (2003). DnaE2 polymerase contributes to *in*
633 *vivo* survival and the emergence of drug resistance in *Mycobacterium tuberculosis*. *Cell*, 113(2),
634 pp. 183–193. doi:10.1016/S0092-8674(03)00270-8.
- 635 Brynildsrud, O.B., Pepperrell, C.S., Suffys, P., Grandjean, L., Monteserin, J., Debech, N., Bohlin, J.,
636 Alfsnes, K., Pettersson, J.O.H., Kirkeleite, I., Fandinho, F., da Silva, M.A., Perdigao, J., Portugal, I.,
637 Viveiros, M., Clark, T., Caws, M., Dunstan, S., Thai, P.V.K., Lopez, B., Ritacco, V., Kitchen, A.,
638 Brown, T.S., van Soolingen, D., O'Neill, M.B., Holt, K.E., Feil, E.J., Mathema, B., Balloux, F.,
639 Eldholm, V. (2018). Global expansion of *Mycobacterium tuberculosis* lineage 4 shaped by
640 colonial migration and local adaptation. *Science Advances*, 4(10), pp. 1–12.
641 doi:10.1126/sciadv.aat5869.
- 642 Bunting, K.A., Roe, S.M. and Pearl, L.H. (2003). Structural basis for recruitment of translesion DNA
643 polymerase Pol IV/DinB to the β -clamp. *EMBO Journal*, 22(21), pp. 5883–5892.
644 doi:10.1093/emboj/cdg568.
- 645 Burnouf, D.Y., Olieric, V., Wagner, J., Fujii, S., Reinbolt, J., Fuchs, R.P.P. and Dumas, P. (2004). Structural
646 and biochemical analysis of sliding clamp/ligand interactions suggest a competition between
647 replicative and translesion DNA polymerases. *Journal of Molecular Biology*, 335(5), pp.
648 1187–1197. doi:10.1016/j.jmb.2003.11.049.
- 649 Chengalroyen, M.D., Mason, M.K., Borsellini, A., Tassoni, R., Abrahams, G.L., Lynch, S., Ahn, Y.-M.,
650 Ambler, J., Young, K., Crowley, B.M., Olsen, D.B., Warner, D.F., Barry, C.E., Boshoff, H.I.M.M.,
651 Lamers, M.H. and Mizrahi, V. (2021) DNA-dependent binding of nargenicin to DnaE1 inhibits
652 replication in *Mycobacterium tuberculosis*. *bioRxiv*, p. 2021.10.27.466036.
653 doi:10.1101/2021.10.27.466036.
- 654 Cirz, R.T., Chin, J.K., Andes, D.R., Crécy-Lagard, V. de, Craig, W.A. and Romesberg, F.E. (2005).
655 Inhibition of mutation and combating the evolution of antibiotic resistance. *PLOS Biology*, 3(6),
656 p. e176. doi:10.1371/JOURNAL.PBIO.0030176.
- 657 Cokol, M., Kuru, N., Bicaç, E., Larkins-Ford, J. and Aldridge, B.B. (2017). Efficient measurement and
658 factorization of high-order drug interactions in *Mycobacterium tuberculosis*. *Science Advances*,
659 3(10). doi:10.1126/sciadv.1701881.
- 660 Cormack, B.P., Valdivia, R.H. and Falkow, S. (1996). FACS-optimized mutants of the green fluorescent
661 protein (GFP). *Gene*, 173(1), pp. 33–38. doi:10.1016/0378-1119(95)00685-0.
- 662 Delincé, M.J., Bureau, J.-B., López-Jiménez, A.T., Cosson, P., Soldati, T. and McKinney, J.D. (2016). A
663 microfluidic cell-trapping device for single-cell tracking of host–microbe interactions. *Lab*
664 *Chip*, 16(17), pp. 3276–3285. doi:10.1039/C6LC00649C.

- 665 Dhar, N. and Manina, G. (2015). Single-cell analysis of mycobacteria using microfluidics and time-
666 lapse microscopy. *Methods in Molecular Biology*, 1285, pp. 241–256.
- 667 Ducret, A., Quardokus, E. and Brun, Y. (2016). MicrobeJ, a tool for high throughput bacterial cell
668 detection and quantitative analysis. *Nature Microbiology*, 1(7), pp. 1–14.
669 doi:10.1038/nmicrobiol.2016.77.MicrobeJ.
- 670 van Eijk, E., Wittekoek, B., Kuijper, E.J. and Smits, W.K. (2017). DNA replication proteins as potential
671 targets for antimicrobials in drug-resistant bacterial pathogens. *Journal of Antimicrobial*
672 *Chemotherapy*, 72(5), pp. 1275–1284. doi:10.1093/JAC/DKW548.
- 673 Einhauer, A. and Jungbauer, A. (2001). The FLAG™ peptide, a versatile fusion tag for the purification
674 of recombinant proteins. *Journal of Biochemical and Biophysical Methods*, 49(1–3), pp. 455–
675 465. doi:10.1016/S0165-022X(01)00213-5.
- 676 Erdem, A.L., Jaszczur, M., Bertram, J.G., Woodgate, R., Cox, M.M. and Goodman, M.F. (2014). DNA
677 polymerase V activity is autoregulated by a novel intrinsic DNA-dependent ATPase. *eLife*,
678 2014(3). doi:10.7554/ELIFE.02384.
- 679 Erill, I., Campoy, S., Mazon, G. and Barbé, J. (2006). Dispersal and regulation of an adaptive
680 mutagenesis cassette in the bacteria domain. *Nucleic Acids Research*, 34(1), pp. 66–77.
681 doi:10.1093/nar/gkj412.
- 682 Farhat, M.R., Freschi, L., Calderon, R., Ioerger, T., Snyder, M., Meehan, C.J., de Jong, B., Rigouts, L.,
683 Sloutsky, A., Kaur, D., Sunyaev, S., van Soolingen, D., Shendure, J., Sacchettini, J. and Murray, M.
684 (2019). GWAS for quantitative resistance phenotypes in *Mycobacterium tuberculosis* reveals
685 resistance genes and regulatory regions. *Nature Communications*, 10(1). doi:10.1038/s41467-
686 019-10110-6.
- 687 Franklin, W.A., Doetsch, P.W. and Haseltine, W.A. (1985). Structural determination of the ultraviolet
688 light-induced thymine-cytosine pyrimidine-pyrimidone (6–4) photoproduct. *Nucleic Acids*
689 *Research*, 13(14), pp. 5317–5325. doi:10.1093/NAR/13.14.5317.
- 690 Gagneux, S. (2018). Ecology and evolution of *Mycobacterium tuberculosis*. *Nature Reviews*
691 *Microbiology*, 16(4), pp. 202–213. doi:10.1038/nrmicro.2018.8.
- 692 Galagan, J.E. (2014). Genomic insights into tuberculosis. *Nature Reviews Genetics*, 15(5), pp. 307–320.
693 doi:10.1038/nrg3664.
- 694 Goodman, M.F., McDonald, J.P., Jaszczur, M.M. and Woodgate, R. (2016) Insights into the complex
695 levels of regulation imposed on *Escherichia coli* DNA polymerase V. *DNA Repair*, 44, pp. 42–50.
696 doi:10.1016/J.DNAREP.2016.05.005.
- 697 Gray, T.A. and Derbyshire, K.M. (2018). Blending genomes: distributive conjugal transfer in

- 698 mycobacteria, a sexier form of HGT. *Molecular Microbiology*, 108(6), pp. 601–613.
699 doi:10.1111/mmi.13971.
- 700 Gruber, A.J., Erdem, A.L., Sabat, G., Karata, K., Jaszczur, M.M., Vo, D.D., Olsen, T.M., Woodgate, R.,
701 Goodman, M.F. and Cox, M.M. (2015). A RecA protein surface required for activation of DNA
702 polymerase V. *PLOS Genetics*, 11(3), p. e1005066. doi:10.1371/JOURNAL.PGEN.1005066.
- 703 Hershberg, R., Lipatov, M., Small, P.M., Sheffer, H., Niemann, S., Homolka, S., Roach, J.C., Kremer, K.,
704 Petrov, D.A., Feldman, M.W. and Gagneux, S. (2008). High functional diversity in
705 *Mycobacterium tuberculosis* driven by genetic drift and human demography. *PLoS Biology*,
706 6(12), pp. 2658–2671. doi:10.1371/journal.pbio.0060311.
- 707 Ippoliti, P.J., DeLateur, N.A., Jones, K.M. and Beuning, P.J. (2012). Multiple strategies for translesion
708 synthesis in bacteria. *Cells*, 1(4), pp. 799–831. doi:10.3390/cells1040799.
- 709 Jaszczur, M.M., Vo, D.D., Stanciauskas, R., Bertram, J.G., Sikand, A., Cox, M.M., Woodgate, R., Mak, C.H.,
710 Pinaud, F. and Goodman, M.F. (2019). Conformational regulation of *Escherichia coli* DNA
711 polymerase V by RecA and ATP. *PLoS Genetics*, 15(2), pp. 1–27.
712 doi:10.1371/journal.pgen.1007956.
- 713 Jiang, Q., Karata, K., Woodgate, R., Cox, M.M. and Goodman, M.F. (2009). The active form of DNA
714 polymerase V is UmuD'2C–RecA–ATP. *Nature*, 460(7253), pp. 359–363.
715 doi:10.1038/nature08178.
- 716 Joseph, A.M., Daw, S., Sadhir, I. and Badrinarayanan, A. (2021). Coordination between nucleotide
717 excision repair and specialized polymerase Dnae2 action enables dna damage survival in non-
718 replicating bacteria. *eLife*, 10. doi:10.7554/ELIFE.67552.
- 719 Kling, A., Lukat, P., Almeida, D.V., Bauer, A., Fontaine, E., Sordello, S., Zaburannyi, N., Herrmann, J.,
720 Wenzel, S., Konig, C., Ammerman, N.C., Barrio, M.B., Borchers, K., Bordon-Pallier, F., Bronstrup,
721 M., Courtemanche, G., Gerlitz, M., Geslin, M., Hammann, P., Heinz, D.W., Hoffmann, H., Klieber,
722 S., Kohlmann, M., Kurz, M., Lair, C., Matter, H., Nuermberger, E., Tyagi, S., Fraise, L., Grosset, J.,
723 H., Lagrange, S., Müller, R.(2015). Targeting DnaN for tuberculosis therapy using novel
724 griselimycins. *Science*, 348(6239), pp. 1106–1112. doi:10.1126/science.aaa4690.
- 725 Ley, S., de Vos, M., Van Rie, A. and Warren, R.M. (2019.) Deciphering within-host microevolution of
726 *Mycobacterium tuberculosis* through whole-genome sequencing: the phenotypic impact and
727 way forward. *Microbiology and Molecular Biology Reviews*, 83(2), pp. 1–21.
- 728 Lin, P.L. and Flynn, J.L. (2018). The end of the binary era: Revisiting the spectrum of tuberculosis. *The*
729 *Journal of Immunology*, 201(9), pp. 2541–2548. doi:10.4049/JIMMUNOL.1800993.
- 730 Luna-Vargas, M.P.A., Christodoulou, E., Alfieri, A., van Dijk, W.J., Stadnik, M., Hibbert, R.G., Sahtoe, D.D.,

- 731 Clerici, M., Marco, V. De, Littler, D., Celie, P.H.N., Sixma, T.K. and Perrakis, A. (2011) Enabling
732 high-throughput ligation-independent cloning and protein expression for the family of
733 ubiquitin specific proteases. *Journal of Structural Biology*, 175(2), pp. 113–119.
734 doi:10.1016/J.JSB.2011.03.017.
- 735 Maslowska, K.H., Makiela-Dzbenska, K. and Fijalkowska, I.J. (2019) The SOS system: A complex and
736 tightly regulated response to DNA damage. *Environmental and Molecular Mutagenesis*, 60(4),
737 pp. 368–384. doi:10.1002/em.22267.
- 738 McHenry, C.S. (2011). Breaking the rules: bacteria that use several DNA polymerase IIIs. *EMBO*
739 *reports*, 12(5), pp. 408–414. doi:10.1038/embor.2011.51.
- 740 Merrikh, H. and Kohli, R.M. (2020). Targeting evolution to inhibit antibiotic resistance. *FEBS Journal*,
741 287(20), pp. 4341–4353. doi:10.1111/febs.15370.
- 742 Minias, A., Brzostek, A. and Dziadek, J.J. (2018). Targeting DNA repair systems in antitubercular drug
743 development. *Current Medicinal Chemistry*, 25(8), pp. 1–12.
744 doi:10.2174/0929867325666180129093546.
- 745 Mittal, P., Sinha, R., Kumar, A., Singh, P., Ngasainao, M.R., Singh, A. and Singh, I.K. (2020). Focusing on
746 DNA repair and damage tolerance mechanisms in *Mycobacterium tuberculosis*: An emerging
747 therapeutic theme. *Current Topics in Medicinal Chemistry*, 20(5), pp. 390–408.
748 doi:10.2174/1568026620666200110114322.
- 749 Nagai, T., Ibata, K., Park, E.S., Kubota, M., Mikoshiba, K. and Miyawaki, A. (2002). A variant of yellow
750 fluorescent protein with fast and efficient maturation for cell-biological applications. *Nature*
751 *Biotechnology*, 20(1), pp. 87–90. doi:10.1038/nbt0102-87.
- 752 Paez Segala, M.G., Sun, M., Shtengel, G., Viswanathan, S., Baird, M., Macklin, J., Patel, R., Allen, J., Howe,
753 E., Piszczek, G., Hess, H., Davidson, M., Wang, Y. and Looger, L. (2015). Fixation-resistant
754 photoactivatable fluorescent proteins for correlative light and electron microscopy. *Nature*
755 *methods*, 12(3), pp. 215–218. doi:10.1038/nmeth.3225.
- 756 Payne, J.L., Menardo, F., Trauner, A., Borrell, S., Gygli, S.M., Loiseau, C., Gagneux, S. and Hall, A.R.
757 (2019). Transition bias influences the evolution of antibiotic resistance in *Mycobacterium*
758 *tuberculosis*. *PLoS*, 17(5), pp. 1–23. doi:10.1101/421651.
- 759 Ragheb, M.N., Thomason, M.K., Hsu, C., Nugent, P., Gage, J., Samadpour, A.N., Kariisa, A., Merrikh, C.N.,
760 Miller, S.I., Sherman, D.R. and Merrikh, H. (2019). Inhibiting the evolution of antibiotic
761 resistance. *Molecular Cell*, 73(1), pp. 157–165.e5. doi:10.1016/j.molcel.2018.10.015.
- 762 Reiche, M.A., Warner, D.F. and Mizrahi, V. (2017). Targeting DNA replication and repair for the
763 development of novel therapeutics against tuberculosis. *Frontiers in Molecular Biosciences*,

- 764 4(November), pp. 1–18. doi:10.3389/fmolb.2017.00075.
- 765 Renzette, N., Gumlaw, N., Nordman, J.T., Krieger, M., Yeh, S.P., Long, E., Centore, R., Boonsombat, R.
766 and Sandler, S.J. (2005). Localization of RecA in *Escherichia coli* K-12 using RecA-GFP.
767 *Molecular Microbiology*, 57(4), pp. 1074–1085. doi:10.1111/j.1365-2958.2005.04755.x.
- 768 Revitt-Mills, S.A. and Robinson, A. (2020). Antibiotic-induced mutagenesis: Under the microscope.
769 *Frontiers in Microbiology*, 0, p. 2611. doi:10.3389/FMICB.2020.585175.
- 770 Riojas, M.A., McGough, K.J., Rider-Riojas, C.J., Rastogi, N. and Hazbón, M.H. (2018). Phylogenomic
771 analysis of the species of the *Mycobacterium tuberculosis* complex demonstrates that
772 *Mycobacterium africanum*, *Mycobacterium bovis*, *Mycobacterium caprae*, *Mycobacterium*
773 *microti* and *Mycobacterium pinnipedii* are later heterotypic synonyms of *Mycobacterium*
774 *tuberculosis*. *International Journal of Systematic and Evolutionary Microbiology*, 68(1), pp. 324–
775 332. doi:10.1099/IJSEM.0.002507.
- 776 Robinson, A., McDonald, J.P., Caldas, V.E.A., Patel, M., Wood, E.A., Punter, C.M., Ghodke, H., Cox, M.M.,
777 Woodgate, R., Goodman, M.F., van Oijen, A.M. and Oijen, A.M. (2015). Regulation of mutagenic
778 DNA polymerase V activation in space and time. *PLOS Genetics*, 11(8), p. e1005482.
- 779 Santi, I., Dhar, N., Bousbaine, D., Wakamoto, Y. and McKinney, J.D. (2013). Single-cell dynamics of the
780 chromosome replication and cell division cycles in mycobacteria. *Nature Communications*,
781 4(May), pp. 1–10. doi:10.1038/ncomms3470.
- 782 Santi, I. and McKinney, J.D. (2015). Chromosome organization and replisome dynamics in
783 *Mycobacterium smegmatis*. *mBio*, 6(1). doi:10.1128/mBio.01999-14.
- 784 Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S., Rueden,
785 C., Saalfeld, S., Schmid, B., Tinevez, J.-Y., White, D.J., Hartenstein, V., Eliceiri, K., Tomancak, P.
786 and Cardona, A. (2012). Fiji: an open-source platform for biological-image analysis. *Nature*
787 *Methods*, 9(7), pp. 676–682. doi:10.1038/nmeth.2019.
- 788 Shtengel, G., Galbraith, J.A., Galbraith, C.G., Lippincott-Schwartz, J., Gillette, J.M., Manley, S., Sougrat, R.,
789 Waterman, C.M., Kanchanawong, P., Davidson, M.W., Fetter, R.D. and Hess, H.F. (2009).
790 Interferometric fluorescent super-resolution microscopy resolves 3D cellular ultrastructure.
791 *Proceedings of the National Academy of Sciences of the United States of America*, 106(9), pp.
792 3125–3130. doi:10.1073/pnas.0813131106.
- 793 Singh, A. (2017). Guardians of the mycobacterial genome: A review on DNA repair systems in
794 *Mycobacterium tuberculosis*. *Microbiology*, 163(12), pp. 1740–1758.
795 doi:10.1099/mic.0.000578.
- 796 Smith, P.A. and Romesberg, F.E. (2007). Combating bacteria and drug resistance by inhibiting

- 797 mechanisms of persistence and adaptation. *Nature Chemical Biology*, 3(9), pp. 549–556.
798 doi:10.1038/nchembio.2007.27.
- 799 Timinskas, K., Balvočiute, M., Timinskas, A. and Venclovas, Č. (2014). Comprehensive analysis of DNA
800 polymerase III α subunits and their homologs in bacterial genomes. *Nucleic Acids Research*,
801 42(3), pp. 1393–1413. doi:10.1093/nar/gkt900.
- 802 Timinskas, K. and Venclovas, Č. (2019). New insights into the structures and interactions of bacterial
803 Y-family DNA polymerases. *Nucleic Acids Research*, 47(9), pp. 4383–4405.
804 doi:10.1093/nar/gkz198.
- 805 Tomasz, M. (1995). Mitomycin C: small, fast and deadly (but very selective). *Chemistry and Biology*,
806 pp. 575–579. doi:10.1016/1074-5521(95)90120-5.
- 807 Veening, J.-W. and Blokesch, M. (2017). Interbacterial predation as a strategy for DNA acquisition in
808 naturally competent bacteria. *Nature Reviews Microbiology*, 15(10), pp. 621–629.
809 doi:10.1038/nrmicro.2017.66.
- 810 Wakamoto, Y., Dhar, N., Chait, R., Schneider, K., Signorino-Gelo, F., Leibler, S. and McKinney, J.D.
811 (2013). Dynamic persistence of antibiotic-stressed mycobacteria. *Science*, 339, pp. 91–95.
- 812 Warner, D.F., Koch, A. and Mizrahi, V. (2015). Diversity and disease pathogenesis in *Mycobacterium*
813 *tuberculosis*. *Trends in Microbiology*, pp. 14–21. doi:10.1016/j.tim.2014.10.005.
- 814 Warner, D.F., Ndwandwe, D.E., Abrahams, G.L., Kana, B.D., Machowski, E.E., Venclovas, Č. and Mizrahi,
815 V. (2010). Essential roles for *imuA'*- and *imuB*-encoded accessory factors in DnaE2-dependent
816 mutagenesis in *Mycobacterium tuberculosis*. *Proceedings of the National Academy of Sciences*
817 *of the United States of America*, 107(29), pp. 13093–13098. doi:10.1073/pnas.1002614107.
- 818 Warner, D.F., Rock, J.M., Fortune, S.M. and Mizrahi, V. (2017). DNA replication fidelity in the
819 *Mycobacterium tuberculosis* complex. In Gagneux, S. (eds) Strain variation in the
820 *Mycobacterium tuberculosis* complex: Its role in biology, epidemiology and control. *Advances*
821 *in Experimental Medicine and Biology*, 1019. Springer, Cham. doi:10.1007/978-3-319-64371-
822 7.
- 823 World Health Organization (2021) *Global Tuberculosis Report*
- 824 von Wintersdorff, C.J.H., Penders, J., van Niekerk, J.M., Mills, N.D., Majumder, S., van Alphen, L.B.,
825 Savelkoul, P.H.M. and Wolffs, P.F.G. (2016). Dissemination of antimicrobial resistance in
826 microbial ecosystems through horizontal gene transfer. *Frontiers in Microbiology*, 0(FEB), p.
827 173. doi:10.3389/FMICB.2016.00173.
- 828